Citigroup’s Global Blood Therapeutics, Inc. GBT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-1,586,334
| Closed | -$108M | – | 6204 |
|
|
2022
Q3 | $108M | Buy |
1,586,334
+1,397,250
| +739% | +$77.1M | 0.08% | 205 |
|
|
2022
Q2 | $6.04M | Buy |
189,084
+143,381
| +314% | +$4.2M | ﹤0.01% | 1426 |
|
|
2022
Q1 | $1.58M | Sell |
45,703
-121,425
| -73% | -$3.63M | ﹤0.01% | 2548 |
|
|
2021
Q4 | $4.89M | Buy |
167,128
+76,303
| +84% | +$2.36M | ﹤0.01% | 1848 |
|
|
2021
Q3 | $2.31M | Sell |
90,825
-23,762
| -21% | -$698K | ﹤0.01% | 2427 |
|
|
2021
Q2 | $4.01M | Buy |
114,587
+15,418
| +16% | +$602K | ﹤0.01% | 2101 |
|
|
2021
Q1 | $4.04M | Buy |
99,169
+85,594
| +631% | +$3.93M | ﹤0.01% | 1942 |
|
|
2020
Q4 | $588K | Buy |
13,575
+4,422
| +48% | +$218K | ﹤0.01% | 4056 |
|
|
2020
Q3 | $505K | Sell |
9,153
-39,424
| -81% | -$2.51M | ﹤0.01% | 3838 |
|
|
2020
Q2 | $3.07M | Buy |
48,577
+2,446
| +5% | +$168K | ﹤0.01% | 2327 |
|
|
2020
Q1 | $2.36M | Buy |
46,131
+1,783
| +4% | +$119K | ﹤0.01% | 2335 |
|
|
2019
Q4 | $3.53M | Buy |
44,348
+6,895
| +18% | +$409K | ﹤0.01% | 2354 |
|
|
2019
Q3 | $1.82M | Buy |
37,453
+11,601
| +45% | +$605K | ﹤0.01% | 2982 |
|
|
2019
Q2 | $1.36M | Buy |
25,852
+14,299
| +124% | +$822K | ﹤0.01% | 3272 |
|
|
2019
Q1 | $612K | Sell |
11,553
-211,582
| -95% | -$10.4M | ﹤0.01% | 3965 |
|
|
2018
Q4 | $9.16M | Buy |
223,135
+187,762
| +531% | +$7.04M | 0.01% | 1322 |
|
|
2018
Q3 | $1.34M | Sell |
35,373
-8,071
| -19% | -$357K | ﹤0.01% | 3153 |
|
|
2018
Q2 | $1.96M | Buy |
43,444
+13,639
| +46% | +$621K | ﹤0.01% | 2694 |
|
|
2018
Q1 | $1.44M | Sell |
29,805
-36,366
| -55% | -$2.03M | ﹤0.01% | 2907 |
|
|
2017
Q4 | $2.6M | Buy |
66,171
+12,014
| +22% | +$449K | ﹤0.01% | 2424 |
|
|
2017
Q3 | $1.68M | Sell |
54,157
-33,662
| -38% | -$947K | ﹤0.01% | 2849 |
|
|
2017
Q2 | $2.4M | Buy |
87,819
+75,980
| +642% | +$2.26M | ﹤0.01% | 2411 |
|
|
2017
Q1 | $436K | Sell |
11,839
-487
| -4% | -$12.3K | ﹤0.01% | 3988 |
|
|
2016
Q4 | $179K | Buy |
12,326
+10,684
| +651% | +$188K | ﹤0.01% | 5361 |
|
|
2016
Q3 | $37K | Buy |
1,642
+92
| +6% | +$1.75K | ﹤0.01% | 5864 |
|
|
2016
Q2 | $26K | Sell |
1,550
-4,104
| -73% | -$82.8K | ﹤0.01% | 6012 |
|
|
2016
Q1 | $90K | Buy |
5,654
+3,541
| +168% | +$62.9K | ﹤0.01% | 5736 |
|
|
2015
Q4 | $68K | Buy |
2,113
+2,111
| +105,550% | +$91.4K | ﹤0.01% | 5684 |
|
|
2015
Q3 | $0 | Buy |
+2
| New | +$94 | ﹤0.01% | 7856 |
|
Other funds holding GBT
Citigroup's GBT Position: Q4 2022 in Review
Citigroup sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,586,334 shares — an estimated $108M sold.
Citigroup first reported a position in GBT in Q3 2015 and held it in 29 quarters. The position peaked at $108M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.
- Citigroup reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
- Citigroup sold 1,586,334 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $108M.
- Citigroup first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 29 quarters.
- Citigroup's Global Blood Therapeutics, Inc. position peaked at $108M in Q3 2022.
- 2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.
Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.